The present invention discloses two new TLR2 agonists, VP1 and VP3, all of which are structural proteins of foot-and-mouth disease virus (FMDV). In addition, residues 91-150 of VP3 are responsible for TLR2 activation of VP3. The VP1 or VP3 or its conjugated protein thereof can be used for stimulating an immune response in a subject. Specifically, in vivo experiments as provided herein showed that VP3-4xM2e is active as a vaccine adjuvant.本發明揭露兩種新穎的類鐸受體-2增效劑,VP1及VP3,其為口蹄疫病毒(foot-and-mouth disease virus,FMDV)之結構蛋白。此外,VP3之第91-150胺基酸是其可以活化類鐸受體-2的主要區域。VP1或VP3或其複合蛋白質因此可被用以促進個體之免疫反應。特定而言,本文所提供之活體內試驗顯示VP3-4xM2e具活性而可作為疫苗佐劑。
